Last updated: September 25, 2026
C1 esterase inhibitor subcutaneous (human), marketed in the United States as Haegarda by CSL Behring, is a plasma-derived biologic for routine prevention of hereditary angioedema (HAE) attacks. Its commercial position is supported by self-administration, established clinical efficacy and demand for long-term prophylaxis. Its main risks are competition from longer-acting monoclonal antibodies and oral kallikrein inhibitors, dependence on human plasma supply, pricing pressure and the absence of separately reported product revenue.
What is C1 esterase inhibitor subcutaneous human?
Haegarda contains human C1 esterase inhibitor derived from donated human plasma. The product replaces functional C1 inhibitor and reduces excessive activation of the contact, complement and coagulation pathways associated with HAE attacks.
The U.S. Food and Drug Administration approved Haegarda in 2017 for routine prophylaxis to prevent HAE attacks in adults and adolescent patients. The labeled regimen is 60 international units per kilogram administered subcutaneously twice weekly. The product is supplied in single-dose vials, including 2,000 IU and 3,000 IU presentations, with administration after reconstitution using the supplied diluent (FDA, 2017).
Haegarda is distinct from Cinryze, another CSL Behring C1 esterase inhibitor product administered intravenously. Haegarda’s commercial differentiation is the ability to support home self-injection without the venous access requirements associated with intravenous prophylaxis.
How large is the hereditary angioedema prophylaxis market?
The HAE market is a specialty orphan-drug market with high treatment value per patient and a limited number of diagnosed patients. Commercial demand is concentrated in North America and Western Europe, where diagnosis, specialist access and reimbursement are strongest.
The market has shifted from reliance on acute treatment toward chronic prophylaxis. Factors supporting prophylaxis demand include:
- Greater recognition of HAE and improved diagnosis of C1-inhibitor deficiency.
- Increased use of preventive therapy in patients with frequent or severe attacks.
- Home administration and reduced dependence on infusion centers.
- Treatment goals focused on attack prevention rather than episodic rescue.
- Expansion of prophylaxis use among adolescents and patients with persistent disease burden.
The relevant competitive market includes plasma-derived C1 inhibitors, recombinant C1 inhibitors, monoclonal antibodies targeting plasma kallikrein and oral kallikrein inhibitors.
| Product |
Active ingredient |
Route |
Principal use |
Commercial sponsor |
| Haegarda |
C1 esterase inhibitor, human |
Subcutaneous |
Routine HAE prophylaxis |
CSL Behring |
| Cinryze |
C1 esterase inhibitor, human |
Intravenous |
Routine HAE prophylaxis |
CSL Behring |
| Takhzyro |
Lanadelumab |
Subcutaneous |
Routine HAE prophylaxis |
Takeda |
| Orladeyo |
Berotralstat |
Oral |
Routine HAE prophylaxis |
Biocryst |
| Ruconest |
C1 esterase inhibitor, recombinant |
Intravenous |
Acute HAE treatment |
Pharming |
| Berinert |
C1 esterase inhibitor, human |
Intravenous |
Acute HAE treatment |
CSL Behring |
Takhzyro is the most direct branded competitor in preventive therapy. Orladeyo competes on oral convenience, while Haegarda competes on a well-established replacement-protein mechanism and self-administered subcutaneous delivery.
How does Haegarda compare with Takhzyro and Orladeyo?
Haegarda’s principal commercial advantage is clinical familiarity with C1 inhibitor replacement and a subcutaneous home-use format. Its principal disadvantage is twice-weekly administration and dependence on plasma-derived manufacturing.
Takhzyro is administered every two weeks for most patients and can be extended to every four weeks in certain circumstances. That dosing interval is a significant adherence and convenience advantage. Takhzyro also uses a monoclonal-antibody platform that avoids direct dependence on donated plasma for the active ingredient.
Orladeyo is taken orally once daily. The oral route expands treatment choice but introduces adherence, drug-interaction and gastrointestinal tolerability considerations. The product has also faced the normal competitive constraints of an oral small molecule entering a market dominated by high-value biologics.
| Factor |
Haegarda |
Takhzyro |
Orladeyo |
| Mechanism |
C1 inhibitor replacement |
Plasma kallikrein inhibition |
Plasma kallikrein inhibition |
| Route |
Subcutaneous |
Subcutaneous |
Oral |
| Typical frequency |
Twice weekly |
Every two or four weeks |
Once daily |
| Manufacturing risk |
Human plasma collection and fractionation |
Recombinant antibody production |
Chemical synthesis |
| Main commercial strength |
Established biologic class and home injection |
Long dosing interval |
Oral administration |
| Main commercial pressure |
Administration frequency and plasma dependence |
High branded cost and injection |
Daily adherence and tolerability |
The strategic question for CSL Behring is whether Haegarda can retain patients who value replacement therapy and whether it can attract patients moving away from intravenous C1 inhibitor treatment. The strategic question for competitors is whether convenience can overcome physician and patient familiarity with C1 inhibitor products.
What clinical evidence supports the commercial position?
The pivotal COMPACT trial evaluated subcutaneous C1 inhibitor for routine HAE prophylaxis. The 60 IU/kg twice-weekly regimen produced a substantial reduction in normalized HAE attack rates compared with placebo. FDA labeling reported a median attack-rate reduction of approximately 90% for the approved dose (FDA, 2017).
The commercial relevance of the data is high because HAE prophylaxis is measured by attack reduction, rescue-treatment use and quality of life. A product that reduces attacks while allowing home administration can reduce emergency care, missed work and reliance on acute-treatment inventory.
Haegarda’s efficacy profile is strongest in patients seeking C1 inhibitor replacement. It is less differentiated in patients whose primary selection criterion is the fewest possible administrations.
What is the financial trajectory of C1 esterase inhibitor subcutaneous human?
CSL Behring does not generally report Haegarda revenue as a separate public line item. CSL reports financial performance primarily by business and product category, including immunoglobulins and other plasma-derived therapies. As a result, Haegarda’s exact annual revenue, gross margin and patient count cannot be isolated reliably from public company filings.
The product’s financial trajectory can be assessed through market and portfolio indicators:
| Financial driver |
Directional impact on Haegarda |
| Growth in diagnosed HAE patients |
Positive |
| Conversion from intravenous prophylaxis |
Positive |
| Expansion of routine prophylaxis |
Positive |
| Competition from Takhzyro |
Negative |
| Competition from Orladeyo |
Negative |
| Plasma collection costs |
Negative if supply tightens |
| Manufacturing scale |
Positive |
| Reimbursement restrictions |
Negative |
| Increased home-treatment preference |
Positive |
| Product-specific price disclosure |
Limited |
Haegarda benefits from CSL Behring’s integrated plasma-collection and fractionation infrastructure. That integration can support supply reliability and manufacturing economics, but it also exposes the product to plasma-collection costs, donor availability, yield variability and broader immunoglobulin-market conditions.
The product is unlikely to be a primary revenue driver at the scale of CSL’s immunoglobulin franchise. Its value is more strategic: it occupies the preventive C1 inhibitor segment, supports portfolio continuity with Cinryze and Berinert, and generates high-value specialty-drug revenue from a small patient population.
Takeda’s disclosures show the commercial scale that can be achieved by a leading HAE prophylaxis product, although Takhzyro revenue is not a direct proxy for Haegarda revenue because the products have different mechanisms, dosing schedules and corporate reporting structures (Takeda Pharmaceutical Company Limited, 2024).
When does Haegarda lose regulatory exclusivity?
Haegarda received U.S. orphan-drug exclusivity when approved in 2017. Orphan exclusivity generally lasts seven years from approval and prevents FDA approval of the same drug for the same indication during that period, subject to statutory exceptions. The principal orphan-exclusivity period therefore ran approximately through 2024.
Orphan exclusivity is separate from patent protection. It does not prevent all competing therapies, including products with different active ingredients or mechanisms. Takhzyro and Orladeyo were able to compete because they are not the same drug as human C1 esterase inhibitor.
Biologic exclusivity also applies under the Public Health Service Act. For a reference biological product, the FDA may not approve a biosimilar application for four years after approval and may not license a biosimilar until 12 years after approval, subject to statutory rules and agency interpretation. Haegarda’s 2017 approval therefore places the 12-year reference-product exclusivity framework around 2029, although the practical impact depends on the product’s regulatory classification, patent estate and any approved biosimilar application (FDA, 2024a).
What patents protect Haegarda and its formulation?
Haegarda is a biologic, so its protection is not assessed through the small-molecule Orange Book framework alone. The relevant FDA database is the Purple Book, which identifies licensed biological products and related reference-product information (FDA, 2024b).
Potential protection for a plasma-derived C1 inhibitor product can include:
- Composition and functional activity of the C1 inhibitor preparation.
- Purification and fractionation methods.
- Stabilized formulations.
- Reconstitution and storage conditions.
- Subcutaneous administration methods.
- Dosage regimens for routine HAE prophylaxis.
- Manufacturing controls and product-quality specifications.
Formulation and manufacturing patents can be commercially important even when the core protein is old. Plasma-derived products are difficult to reproduce consistently because manufacturing involves biological source material, fractionation, purification, viral clearance and quality-control requirements. A competing manufacturer must satisfy both patent constraints and demanding biologics manufacturing standards.
No conventional generic substitution pathway applies to Haegarda. A competitor would need to pursue a biologics pathway or obtain approval for a distinct C1 inhibitor product. FDA substitution depends on a product being designated interchangeable, not merely biosimilar.
What biosimilar and generic entry risks exist?
There was no widely established U.S. biosimilar competitive threat to Haegarda in the public market through 2024. The near-term threat is more likely to come from branded mechanism competitors than from a direct biosimilar.
A future C1 inhibitor biosimilar would face several barriers:
- Demonstrating analytical similarity to a complex plasma-derived product.
- Establishing comparable pharmacokinetics and immunogenicity.
- Reproducing clinically relevant functional activity.
- Securing a reliable plasma or alternative source strategy.
- Building manufacturing capacity that satisfies biologics quality standards.
- Resolving patent and regulatory exclusivity issues.
- Obtaining payer access against an established branded product.
A biosimilar could create material price pressure if it achieved interchangeable status and payer adoption. The more immediate commercial risk is formulary pressure from Takhzyro and Orladeyo, which can win patients without waiting for a direct Haegarda substitute.
What patent litigation and settlement issues affect Haegarda?
Publicly disclosed commercial risk is centered more on competition and reimbursement than on a major reported Paragraph IV litigation campaign. Paragraph IV challenges are relevant to small-molecule drugs filed under the Hatch-Waxman framework. Haegarda is regulated as a biologic, so biosimilar litigation follows the Biologics Price Competition and Innovation Act patent-dispute framework rather than the standard Orange Book Paragraph IV process.
The absence of a prominent direct biosimilar challenge reduces near-term launch uncertainty but does not eliminate long-term patent risk. A competing biologic could contest patents covering manufacturing, formulation or administration methods. Patent settlements, if reached, would need to be assessed against the timing of any biosimilar license and the scope of the challenged claims.
How strong is the Haegarda patent and market estate?
Haegarda has a moderate-to-strong commercial estate but a less durable competitive position than a product protected by a long-lived composition-of-matter patent.
Its strengths are:
- Orphan-disease pricing.
- Established clinical evidence.
- Subcutaneous home administration.
- CSL Behring’s plasma and manufacturing infrastructure.
- Physician familiarity with C1 inhibitor replacement.
- High barriers to reproducing plasma-derived biologics.
Its weaknesses are:
- Twice-weekly dosing.
- Competition from longer-acting and oral prophylaxis.
- Limited product-level financial transparency.
- Exposure to plasma supply and manufacturing costs.
- Limited ability to block products with different mechanisms.
- Eventual biosimilar and manufacturing-method challenges.
The product’s commercial durability depends more on execution, supply reliability, payer positioning and patient retention than on a single patent expiry date.
What generic launch scenarios are most likely?
Scenario 1: Continued branded competition
This is the most likely near-term scenario. Haegarda retains a stable position among patients who prefer C1 inhibitor replacement, while Takhzyro and Orladeyo capture patients prioritizing longer dosing intervals or oral therapy.
Scenario 2: Increased conversion to Takhzyro
This scenario would pressure Haegarda if physicians and patients place greater value on monthly or less frequent administration. The risk is greatest among patients with stable disease who do not require the specific pharmacologic profile of C1 inhibitor replacement.
Scenario 3: Oral prophylaxis expansion
Greater adoption of Orladeyo could reduce injectable prophylaxis demand, especially among patients with injection fatigue or needle aversion. Treatment persistence and real-world efficacy will determine whether oral convenience offsets daily dosing.
Scenario 4: Direct biologic competition
A biosimilar or follow-on C1 inhibitor could pressure price and market share, but development, manufacturing and regulatory complexity make this a longer-term risk than branded competition.
What is the geographic coverage and regulatory status?
Haegarda is approved in the United States. CSL Behring also markets C1 inhibitor products internationally, although brand names, formulations, indications and regulatory status vary by country.
The United States remains commercially important because of high specialty-drug prices, established HAE diagnosis and broad use of home-administered prophylaxis. Europe has meaningful demand but greater health-technology assessment and reimbursement variation. Emerging markets have lower diagnosed-patient counts, more limited specialist access and greater affordability constraints.
Key Takeaways
- Haegarda is the principal U.S. subcutaneous human C1 esterase inhibitor for routine HAE prophylaxis.
- Its core advantages are proven attack reduction, home administration and CSL Behring’s plasma-derived manufacturing platform.
- Its main competitive threats are Takhzyro’s extended dosing interval and Orladeyo’s oral route.
- CSL Behring does not separately disclose Haegarda revenue, so financial analysis must rely on portfolio and market proxies.
- U.S. orphan exclusivity from the 2017 approval period ran approximately through 2024.
- Biologic exclusivity and patent protection extend beyond orphan exclusivity, but exact launch timing for a direct competitor depends on the relevant patent and regulatory framework.
- Direct biosimilar risk was limited through 2024; branded mechanism competition is the more immediate threat.
- Long-term value depends on patient retention, reimbursement, plasma supply, manufacturing reliability and the ability to defend twice-weekly dosing against more convenient alternatives.
FAQs
Is Haegarda the same as Cinryze?
No. Both contain human C1 esterase inhibitor, but Haegarda is administered subcutaneously for routine prophylaxis, while Cinryze is administered intravenously.
Is Haegarda interchangeable with Takhzyro?
No. Haegarda replaces C1 inhibitor, while Takhzyro inhibits plasma kallikrein. They are separate biologic products with different mechanisms and dosing schedules.
Does Haegarda have a generic version?
No conventional generic version exists. Any direct follow-on would likely require a biosimilar or other biologics approval pathway.
Does Haegarda appear in the Orange Book?
Biologic reference-product information is generally evaluated through the FDA Purple Book rather than the Orange Book. The Orange Book is primarily associated with approved small-molecule drug products and listed patents.
What is the largest commercial risk to Haegarda?
The largest near-term risk is substitution by competing preventive therapies, especially longer-acting subcutaneous lanadelumab and oral berotralstat, rather than conventional generic entry.
References
-
U.S. Food and Drug Administration. (2017). HAEGARDA prescribing information. https://www.accessdata.fda.gov
-
U.S. Food and Drug Administration. (2024a). Biosimilar and interchangeable biologics. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilar-biological-products
-
U.S. Food and Drug Administration. (2024b). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
-
CSL Limited. (2024). Annual report 2024. https://www.csl.com
-
Takeda Pharmaceutical Company Limited. (2024). Annual report 2024. https://www.takeda.com
-
Zuraw, B. L., Busse, P. J., White, M., Jacobs, J., Lumry, W., Baker, J., ... Cicardi, M. (2010). Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. New England Journal of Medicine, 363(6), 513-522.
